Deep Track Capital PTGX Position
Exited8-Fund ConvergenceDeep Track Capital exited their position in Protagonist Therapeutics Inc. (PTGX) in Q1 2024, after holding the stock for 2 quarters.
The position was first reported in Q4 2023 and has been tracked across 2 quarterly 13F filings.
PTGX is a convergence signal: 8 specialist biotech funds hold this stock, suggesting high institutional conviction.
Short interest stands at 15.1% of float with 12.4 days to cover, indicating significant bearish positioning against the stock.
About Protagonist Therapeutics Inc.
Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with polycythemia vera and hereditary hemochromatosis, as well as for the treatment of other blood disorders; PN-943, an oral, alpha-4-beta-7 integrin- specific antagonist peptide that is in Phase II clinical trials for treating inflammatory bowel disease (IBD); and PN-235, an orally delivered interleukin-23 receptor specific antagonist for the treatment of IBD and non-IBD indications. The company has a license and collaboration agreement with Janssen Biotech, Inc. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.
Full company profile →Short Interest
15.1%
12.4 days to cover
Deep Track Capital PTGX Position History
Frequently Asked Questions
Does Deep Track Capital own PTGX?
No. Deep Track Capital exited their position in Protagonist Therapeutics Inc. (PTGX) in Q1 2024. They previously held the stock for 2 quarters.
How many hedge funds own PTGX?
8 specialist biotech hedge funds currently hold PTGX, including RTW Investments, BVF Partners, Perceptive Advisors and 5 more. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did Deep Track Capital first buy PTGX?
Deep Track Capital's position in PTGX was first reported in Q4 2023. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is Deep Track Capital's PTGX position increasing or decreasing?
Deep Track Capital completely exited their PTGX position in the most recent quarter.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
PTGXCompany Page →
All fund holders, insider trades, catalysts, and cash runway
Deep Track CapitalPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →